Last reviewed · How we verify

Perindopril + Indapamide — Competitive Intelligence Brief

Perindopril + Indapamide (Perindopril + Indapamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor + thiazide-like diuretic combination. Area: Cardiovascular.

marketed ACE inhibitor + thiazide-like diuretic combination Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Perindopril + Indapamide (Perindopril + Indapamide) — Centre for Chronic Disease Control, India. Perindopril inhibits ACE to reduce angiotensin II formation and lower blood pressure, while indapamide acts as a thiazide-like diuretic to promote sodium and water excretion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Perindopril + Indapamide TARGET Perindopril + Indapamide Centre for Chronic Disease Control, India marketed ACE inhibitor + thiazide-like diuretic combination Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor + thiazide-like diuretic combination class)

  1. Centre for Chronic Disease Control, India · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Perindopril + Indapamide — Competitive Intelligence Brief. https://druglandscape.com/ci/perindopril-indapamide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: